About Medicinal Tirzepatide

Publisher entity

Medicinal Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide, the dual GIP and GLP-1 receptor agonist. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "medicinal" in this site's name is an editorial framing of the research context — tirzepatide is an FDA-approved pharmaceutical whose clinical trial record is what this site documents. It is not a claim that this site provides medical services, fills prescriptions, or functions as a healthcare provider of any kind.

Tirzepatide regulatory history

Is tirzepatide FDA approved? FDA approved tirzepatide for type 2 diabetes in May 2022. FDA approved tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity in November 2023. FDA approved tirzepatide for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 ^[16].

Timeline: — May 2022: T2DM indication approved (NDA 215866) — November 2023: Chronic weight management indication approved (NDA 217806) — December 2024: Obstructive sleep apnea indication approved

This site does not discuss tirzepatide under any brand name. The compound is referred to by its International Nonproprietary Name (INN) throughout.

Editorial standards

Every quantitative claim on this site is cited to a peer-reviewed publication, FDA labeling, or registered trial record. Citation numbers in [brackets] correspond to entries in the reference index at /references. PMIDs, DOIs, and direct URLs are provided for each reference.

This site does not publish anecdotal reports, manufacturer claims, or unverified community experience. The SURPASS and SURMOUNT clinical trial programs together constitute the primary evidentiary basis for the content — nine phase-3 programs, over 20,000 trial participants across the cited primary analyses.

Content on /dosage that references FDA-labeled dose ranges does so in the context of documenting what was administered in clinical trials and what appears in approved labeling — not as a personal recommendation. Tirzepatide dosage studied in clinical trials is documented from primary trial protocols and FDA prescribing information only.

For questions about this editorial project, see the contact page.